Palvella Therapeutics, Inc. (PVLA)

NASDAQ: PVLA · Real-Time Price · USD

20.94

+0.43 (2.10%)

Jun 20, 2025, 9:41 AM - Market open

Palvella Therapeutics Employees

Palvella Therapeutics had 14 employees as of December 31, 2024.

Employees

14

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,634,929

Market Cap

231.51M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

PVLA News

2 days ago - Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - GlobeNewsWire
11 days ago - Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - GlobeNewsWire
24 days ago - Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - GlobeNewsWire
5 weeks ago - Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
6 weeks ago - Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 - GlobeNewsWire
6 weeks ago - Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 - GlobeNewsWire
2 months ago - Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology - GlobeNewsWire
2 months ago - Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - GlobeNewsWire